| Literature DB >> 15878841 |
Munish C Gupta1, Safdar N Khan.
Abstract
We are now entering an exciting new era in spinal surgery where the inherent osteoinductive capacity of the body has been harnessed for bone formation for therapeutic purposes. Recombinant bone morphogenetic proteins have been extensively studied in both the pre-clinical and clinical arena for spinal fusion with considerable success. The challenges facing spine surgeons now is the development of site-specific carriers and optimal doses for these growth factors. This review highlights the recent advances in this regard.Mesh：
Substances：
Year: 2005 PMID： 15878841 DOI： 10.1016/j.cytogfr.2005.02.004
Source DB: PubMed Journal: Cytokine Growth Factor Rev ISSN： 1359-6101 Impact factor: 7.638